MRG003治疗肝转移与EGFR表达亚组分析

A brief discussion of the subgroup analysis results: The main focus is on the outcomes of patients with liver metastasis, EGFR expression level subgroups, and those who crossed over to the MRG003 group. From the point estimates of the HR for PFS in both groups, it appears that there is a certain relationship between EGFR expression levels and the benefits of MRG003. However, due to the small sample size of low-expression cases (which is related to the high expression of EGFR in most NPC patients), further evidence is still needed to confirm the potential benefit of EGFR-ADC. In this study, patients with liver metastasis showed a significant PFS benefit from MRG003 treatment, which may be related to the poor efficacy of single-agent chemotherapy in this subgroup (with an mPFS of only about 1 month). This indicates that MRG003 provides a treatment option for patients with extremely limited therapeutic choices and poor prognosis.